Skip to content
Kristen M. O'Dwyer, M.D.

Kristen M. O'Dwyer, M.D.

Hematology & Oncology , Cancer

5 out of 5 stars
UR Medicine Faculty The University of Rochester Medical Faculty Group (URMFG) consists of over 900 specialist and primary care providers spanning 19 departments. URMFG is certified by the National Committee for Quality Assurance.
Accountable Health Partner Accountable Health Partners (AHP) is a network of over 2,000 community and UR medical faculty and a dozen leading hospitals throughout the region. AHP offers a full range of care.
Accepting New Patients


About Me

Faculty Appointments

Associate Professor - Department of Medicine, Hematology/Oncology (SMD)

Associate Professor - Cancer Center - Joint


Residency & Fellowship

Fellowship, Medical Oncology, Memorial Sloan-Kettering Cancer Center. 2006 - 2010

Residency, Internal Medicine, New York Presbyterian Hospital/Weill Cornell. 2005 - 2006

Internship, Internal Medicine, New York Presbyterian Hospital/Weill Cornell. 2004 - 2005

Internship, Pathology, National Cancer Institute/National Institute of Health. 2003 - 2004


MD | University of Wisconsin Medical School-Madison. 2003


Young Investigator Award. 2016

Wilmot Cancer Research Fellowship. 2010 - 2013

Young Investigator Award. 2009 - 2010

Clinical Scholars Biomedical Research Fellowship. 2007 - 2009

National Institutes of Health General Research Loan Repayment Program. 2003 - 2004

Howard Hughes Medical Institute Research Training Fellowship for Medical Students. 2002 - 2003

NIH Research Scholar, Cloister Program. 2000 - 2002

Medical Student Teaching Fellowship. Dept. of Physiology. 1998


Clinical Trials

A Randomized Phase II Study Comparing Inotuzumab Plus Chemotherapy Versus Standard Chemotherapy in Older Adults With Philadelphia-Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Lead Researcher: Kristen M O'Dwyer

This phase II trial compares the combination of inotuzumab ozogamicin and chemotherapy to the usual chemotherapy in treating patients with B-cell acute lymphoblastic leukemia or B-cell lymphoblastic lymphoma. Inotuzumab ozogamicin is a monoclonal ant...

A Phase III Randomized Trial of Steroids+Tyrosine Kinase Inhibitor Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

Lead Researcher: Kristen M O'Dwyer

This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ...

A Phase 4, Multi-center Open-label Feasibility Study to Evaluate Outpatient Blinatumomab Administration in Adult Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL) in Complete Hematologic Remission

Lead Researcher: Kristen M O'Dwyer

The study aims to determine the safety and feasibility of complete outpatient blinatumomab administration for subjects with minimal/measurable residual disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL).

A Phase II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Lead Researcher: Kristen M O'Dwyer

This phase II trial studies how well OBI-3424 works in treating patients with T-cell acute lymphoblastic leukemia that has come back (relapsed) or does not response to treatment (refractory). Drugs used in chemotherapy, such as OBI-3424, work in diff...

Understanding Causes of Outcome Disparities in Adolescents and Young Adults (AYA) with Acute Lymphoclastic Leukemia (ALL)

Lead Researcher: Kristen M O'Dwyer

We will establish two prospective groups of patients with Acute Lymphoclastic Leukemia (ALL): "Cohort A" will be enrolled on the study at the time of diagnosis while "Cohort B" will be enrolled during maintenance chemotherapy.


Journal Articles

Optimal Approach to T-cell ALL. Hematology Am Soc Hematol Educ Program

O'Dwyer KM.

2022; 2022 (1):197-205.

KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study.

Shah BD; Ghobadi A; Oluwole OO; Logan AC; Boissel N; Cassaday RD; Leguay T; Bishop MR; Topp MS; Tzachanis D; O'Dwyer KM; Arellano ML; Lin Y; Baer MR; Schiller GJ; Park JH; Subklewe M; Abedi M; Minnema MC; Wierda WG; DeAngelo DJ; Stiff P; Jeyakumar D; Feng C; Dong J; Shen T; Milletti F; Rossi JM; Vezan R; Masouleh BK; Houot R.

2021; Lancet 2021;398:491-502.

American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.

Sekeres MA; Guyatt G; Abel G; Alibhai S; Altman JK; Buckstein R; Choe H; Desai P; Erba H; Hourigan CS; LeBlanc TW; Litzow M; MacEachern J; Michaelis LC; Mukherjee S; O'Dwyer K; Rosko A; Stone R; Agarwal A; Colunga-Lozano LE; Chang Y; Hao Q; Brignardello-Petersen R.

2020; .

Treatment Strategies for Adolescent and Young Adult Patients with Acute Myeloid Leukemia

O'Dwyer KM; Freyer DR; and Horan JT.

2018; .

Evolution of acute myelogenous leukemia stem cell properties after treatment and progression.

Ho TC, LaMere M, Stevens BM, Ashton JM, Myers JR, O'Dwyer KM, Liesveld JL, Mendler JH, Guzman M, Morrissette JD, Zhao J, Wang ES, Wetzler M, Jordan CT, Becker MW

Blood.. 2016 September 29128 (13):1671-8. Epub 07/15/2016.

Chemoenzymatic synthesis and antileukemic activity of novel C9- and C14-functionalized parthenolide analogs.

Tyagi V, Alwaseem H, O'Dwyer KM, Ponder J, Li QY, Jordan CT, Fasan R

Bioorganic & medicinal chemistry.. 2016 September 124 (17):3876-3886. Epub 06/16/2016.

When to Treat Adults Like Children: Optimizing Therapy for Lymphoblastic Lymphoma in Young Adults.

O'Dwyer KM, Advani AS

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2016 February 2034 (6):533-8. Epub 12/23/2015.

Preleukemic or smoldering" chronic myelogenous leukemia (CML):BCR-ABL1 positive: A brief case report.

Bennett, JM; Dsouza, KG; Patel, M; O'Dwyer KM.

Leukemia research reports. 2015; 4(1): 12-4.

Discovery of potent parthenolide-based antileukemic agents enabled by late-stage P450-mediated C-H functionalization.

Kolev JN, O'Dwyer KM, Jordan CT, Fasan R

ACS chemical biology.. 2014 January 179 (1):164-73. Epub 11/08/2013.

A phase I study of decitabine and rapamycin in relapsed/refractory AML.

Liesveld JL, O'Dwyer K, Walker A, Becker MW, Ifthikharuddin JJ, Mulford D, Chen R, Bechelli J, Rosell K, Minhajuddin M, Jordan CT, Phillips GL

Leukemia research.. 2013 December 37 (12):1622-7. Epub 09/08/2013.

Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells.

Pei S, Minhajuddin M, Callahan KP, Balys M, Ashton JM, Neering SJ, Lagadinou ED, Corbett C, Ye H, Liesveld JL, O'Dwyer KM, Li Z, Shi L, Greninger P, Settleman J, Benes C, Hagen FK, Munger J, Crooks PA, Becker MW, Jordan CT

The Journal of biological chemistry.. 2013 November 22288 (47):33542-33558. Epub 10/02/2013.

BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells.

Lagadinou ED, Sach A, Callahan K, Rossi RM, Neering SJ, Minhajuddin M, Ashton JM, Pei S, Grose V, O'Dwyer KM, Liesveld JL, Brookes PS, Becker MW, Jordan CT

Cell stem cell.. 2013 March 712 (3):329-41. Epub 01/17/2013.

Azacitidine and the beginnings of therapeutic epigenetic modulation.

O'Dwyer K, Maslak P

Expert opinion on pharmacotherapy.. 2008 August 9 (11):1981-6. Epub 1900 01 01.

Microarrays in breast cancer research and clinical practice--the future lies ahead.

Gruvberger-Saal SK, Cunliffe HE, Carr KM, Hedenfalk IA

Endocrine-related cancer.. 2006 December 13 (4):1017-31. Epub 1900 01 01.

Generation and analysis of melanoma SAGE libraries: SAGE advice on the melanoma transcriptome.

Weeraratna AT, Becker D, Carr KM, Duray PH, Rosenblatt KP, Yang S, Chen Y, Bittner M, Strausberg RL, Riggins GJ, Wagner U, Kallioniemi OP, Trent JM, Morin PJ, Meltzer PS

Oncogene.. 2004 March 1823 (12):2264-74. Epub 1900 01 01.

Genomic and proteomic approaches for studying human cancer: prospects for true patient-tailored therapy.

Carr KM, Rosenblatt K, Petricoin EF, Liotta LA

Human genomics.. 2004 January 1 (2):134-40. Epub 1900 01 01.

Gene-expression profiling in human cutaneous melanoma.

Carr KM, Bittner M, Trent JM

Oncogene.. 2003 May 1922 (20):3076-80. Epub 1900 01 01.

Early results from a dioxin genome project.

Thomas, RS; Rank, DR; Jovanovich, S; Hogenesch, JB; Zastro, GM; Carr, KM; Bradfield, CA.

Toxicologist. 1999; : 307.

Molecular characterization of the murine HIF-1 alpha locus.

Luo, G; Gu, Y; Jain, S; Chan, WK; Carr, KM; Hogenesch, JB; Zastro, GM; Carr, KM; Bradfield, CA.

Gene Expressions. 1997; : 287-99.

Identification of palmitoylation sites within the L-type calcium channel beta-two subunit and effects on channel function.

Chien,AJ; Carr, KM; Shirokov, RE; Rios, E; Hosey, MM.

Journal of Biological Chemistry. 1996; : 26465-68.

Semin Hematol. The challenge to further improvements in survival of patients with T-ALL: Current treatments and new insights from disease pathogenesis.

O'Dwyer K.

KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results.

Shah BD; Bishop MR; Oluwole OO; Logan AC; Baer MR; Donnellan WB; O'Dwyer KM; Holmes H; Arellano ML; Ghobadi A; Pagel JM; Lin Y; Cassaday RD; Park JH; Abedi M; Castro JE; DeAngelo DJ, Malone AK; Mawad R; Schiller GJ; Rossi JM; Bot A; Shen T; Goyal L; Jain RK; Vezan R; Wierda WG.

Blood. 2021 138(1):11-22.

Ratings & Comments

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.


During this visit, did this provider spend enough time with you?

4.9 stars

During this visit, did this provider show respect for what you had to say?

5.0 stars

During this visit, did this provider give you easy to understand information about these health questions or concerns?

5.0 stars

During this visit, did this provider listen carefully to you?

5.0 stars

During this visit, did this provider explain things in a way that was easy to understand?

4.9 stars

Patient Comments

5.0 stars

I have a great team of doctors at the U of R

Jan 18, 2024

5.0 stars

I would definitely recommend Dr. O'Dwyer as well as the Wilmont Cancer Center to anyone going through cancer. Best care I have ever seen!

Aug 31, 2023

5.0 stars

Dr. O'Dwyer is excellent.....very caring and easy to talk to. Explains everything.

Aug 12, 2023

5.0 stars

Dr. O'Dwyer always takes time to address concerns. The Lab (Blood Lab) are also always pleasant.

May 04, 2023

4.6 stars


Apr 11, 2023

5.0 stars

Couldn't like a doctor more than I like Dr. O'Dwyer. She instills a great deal of confidence in me concerning her skills & knowledge.

Jul 28, 2022

5.0 stars

Excellent care.

May 25, 2022

5.0 stars

Cannot say enough about my level of trust I have for Dr. O'Dwyer.

Feb 14, 2022